Home - Chinese Journal of Cancer Research

2025 Impact Factor of CJCR: 6.7
Journal Citation Reports ™, Clarivate Analytics

Preface to Special Issue: Breakthroughs in malignancy therapy: New advances and emerging trends——Awakening immune system: The new era of radioimmunotherapy

Over the past few decades, the therapeutic landscape of malignancies has undergone profound transformations. Malignancy therapy has transitioned from traditional, non-specific modalities into a sophisticated era defined by precision medicine, multi-omics, and immunology. Novel immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines have rewritten historical survival curves for patients with malignancies. It is against this backdrop that our journal launches this special issue: Breakthroughs in Malignancy Therapy: New Advances and Emerging Trends.

Updates of CSCO guidelines for colorectal cancer version 2026

Colorectal cancer ranks third in incidence worldwide but second in mortality. In China, colorectal cancer is the second most common cancer and the most prevalent gastrointestinal malignancy, with both incidence and mortality continuing to rise. In 2017, the Chinese Society of Clinical Oncology (CSCO) issued its guidelines for colorectal cancer. These guidelines are updated annually to incorporate the latest clinical research findings, therapeutic agents, and expert opinions. This article describes the updates made in the 2026 version compared with the 2025 version.

Updates of CSCO guidelines for diagnosis and treatment of acute leukemia: 2026 edition

A nationwide registry analysis estimated 43,275 new cases of acute leukemia in China in 2019. Among adults, 5-year overall survival was 23.9% for acute myeloid leukemia excluding acute promyelocytic leukemia, 82.5% for APL, and 30.1% for acute lymphoblastic leukemia. The Chinese Society of Clinical Oncology (CSCO) guidelines for hematological malignancies were first published in 2020 and are revised regularly to incorporate emerging evidence, domestic drug approvals, accessibility, and clinical practice needs in China. This article describes the verified changes in acute leukemia management in the 2026 edition relative to the 2025 edition.

Updates of CSCO guidelines for diagnosis and treatment of lymphoma: 2026 edition

Lymphoma is one of the most common hematological malignancies. In China, an estimated 5,840 new cases and 2,232 deaths were attributable to Hodgkin lymphoma, whereas 108,327 new cases and 39,905 deaths were attributable to non-Hodgkin lymphoma in 2023. The Chinese Society of Clinical Oncology (CSCO) first issued its guidelines for the diagnosis and treatment of lymphoma in 2018 and has updated them annually thereafter, incorporating evidence from high-quality clinical studies as well as evolving treatment availability. This article summarizes the key updates introduced in the 2026 edition relative to the 2025 edition.

Leukemia epidemiology in China: Burden, trends, and determinants in the 21st century

This comprehensive review integrates population-based registries, hospital databases and Global Burden of Disease data to describe the evolving leukemia burden in China from 2000 to 2022. The overall incidence has stabilized nationally, but the absolute number of cases continues to increase as the population ages. A bimodal age pattern persists, with acute leukemias clustering in young children and older adults, while chronic forms predominate in mid-to-late life, and males are consistently more affected by all subtypes. Rapid expansion of haploidentical hematopoietic stem cell transplantation has resulted in marked survival gains for both acute myeloid leukemia and acute lymphoblastic leukemia, and its seamless integration with molecularly targeted agents, venetoclax-based regimens and chimeric antigen receptor T-cell therapy has transformed acute leukemias into potentially curable diseases for an expanding proportion of patients. In parallel, universal access to tyrosine kinase inhibitors and standardized molecular monitoring have turned chronic myeloid leukemia into a manageable chronic condition

‹ ›

Vol 38, No 5 (Oct 2026)

Research Highlight

Comprehensive management of immune-related adverse events in the era of cancer immunotherapy: From reactive treatment to risk stratification and therapeutic coordination

Hanping Wang, Binhe Tian

Pages: 555-558 HTML

From stimulator of interferon genes (STING) agonism to STING programming: Opportunities for mRNA cancer vaccines

Zheqi Zhou, Qiushi Qin, Chuanhui Han

Pages: 559-562 HTML

Barriers and promising avenues for clinical translation of neoantigen-based cancer vaccines

Xinyu Du, Shibo Wang, Shuang Wang, Wei Wei, Yongzhan Nie

Pages: 563-566 HTML

Beyond visible anatomy: From CT images to digital biomarkers in gastric cancer

Minghao Qin, Jia Fu, Mengjie Fang, Tongyu Zhao, Yuanhe Tian, Ling Wu, Jie Tian, Xuebin Xie, Di Dong

Pages: 567-571 HTML

Advances in systemic therapy for renal cell carcinoma from treatment intensification to individualized treatment selection

Xinyuan Wei, Xu Hu, Zhenhua Liu, Hao Zeng

Pages: 572-575 HTML

Original Article

Statistical cure, dynamic survivorship, and landmark-updated risk assessment in T-lymphoblastic lymphoma: A multicenter cohort study with population-based corroboration

Jin Chai, Yunyan Sun, Xuewen Lei, Linjun Zhao, Jie Chen, Ni An, Wenhui Zhang, Yue Wang, Lingyan Ping, Yuqin Song, Hui Yu

Pages: 576-589 HTML

A progenitor-exhausted (Tpex)-like CD8⁺ T-cell compartment extends across axillary lymphatic basin beyond sentinel lymph nodes in breast cancer

Songhan Li, Bo Liu, Liu Yang, Chaobin Wang, Wei Du, Shuwei Zhang, Ran Gao, Jingyu Zhang, Huan Li, Yujing Li, Yiting Chen, Miao Liu, Hai Qi, Shu Wang

Pages: 590-605 HTML

Molecular subtyping of brain metastasis-related genes in lung adenocarcinoma via scRNA-seq and bulk RNA-seq integration: A focus on TPX2

Gang Xiao, Jiaoyang Ning, Su Wen, Liu Chen, Hao Wen, Keqin Zhang, Jie Yang, Qi Wu, Jing Zhang, Guilong Tanzhu, Min Su, Haibin Deng, Rongrong Zhou

Pages: 606-623 HTML

Identifying tumor microenvironment subtypes in pancreatic neuroendocrine tumors using digital spatial profiling

Xiongxiong Lu, Xiaomei Tang, Ziyu Chen, Fanlu Li, Yu Jiang, Yihan Dong, Zhihan Zhang, Jiabin Jin, Zhiwei Xu, Xiaxing Deng, Hao Chen, Chenghong Peng, Wei Huang, Da Fu, Jing Xie

Pages: 624-644 HTML

Olaparib delays resolution of irreversible electroporation-induced DNA damage and enhances short-term antitumor activity in prostate cancer models

Jiacheng Xiang, Zhiyu Xia, Yuan Wang, Shaogang Wang, Qidong Xia

Pages: 645-660 HTML

A patient-derived bladder cancer organoid and xenograft platform for personalized drug response prediction and salvage therapeutics screening

Junlin Lu, Kaiwen Jie, Chu Liu, Jiajian Lai, Peng Xu, Xinxin He, Kanghua Xiao, Yating Chen, Sen Liu, Zehua Chen, Jianhui Zhang, Zegeng Yang, Shizhi Lin, Qiang Zhang, Ming Huang, Liang Cheng, Siting Chen, Jianmei Zhong, Sheng Li, Hong Li, Xu Chen

Pages: 661-678 HTML

Editorial

Updates of CSCO guidelines for diagnosis and treatment of acute leukemia: 2026 edition

Hongye Gao, Erlie Jiang

Pages: 393-398 HTML

CSCO Guidelines

Updates of CSCO guidelines for diagnosis and treatment of lymphoma: 2026 edition

Weiping Liu, Donglu Zhao, Jun Ma, Jun Zhu, Yuqin Song

Pages: 336-339 HTML

Updates of CSCO guidelines for colorectal cancer version 2026

Xian Zhong, Jinyi Chen, Yan Zhang, Hanguang Hu, Shanshan Weng, Suzhan Zhang, Ying Yuan

Pages: 329-335 HTML

Updates of CSCO guidelines for colorectal cancer version 2025

Demin Lu, Caixia Dong, Kailai Wang, Chenyang Ye, Liubo Chen, Ying Yuan, Hanguang Hu

Pages: 297-302 HTML

CSCO guidelines for colorectal cancer version 2024: Updates and discussions

Liubo Chen, Hanguang Hu, Ying Yuan, Shanshan Weng

Pages: 233-239 HTML

CSCO guidelines for colorectal cancer version 2023: Updates and insights

Mi Mi, Shanshan Weng, Ziheng Xu, Hanguang Hu, Yi Wang, Ying Yuan

Pages: 233-238 HTML

CSCO guidelines for colorectal cancer version 2022: Updates and discussions

Zhijun Yuan, Shanshan Weng, Chenyang Ye, Hanguang Hu, Suzhan Zhang, Ying Yuan

Pages: 67-70 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Jun Zhu, Jun Ma, Union for China Lymphoma Investigators of Chinese Society of Clinical Oncology

Pages: 289-301 HTML

Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020

Caixia Dong, Yuwei Ding, Shanshan Weng, Guichao Li, Yanqing Huang, Hanguang Hu, Zhen Zhang, Suzhan Zhang, Ying Yuan

Pages: 302-307 HTML

Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019

Shanshan Weng, Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 403-407 HTML

Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018

Ying Yuan, Xicheng Wang, Gong Chen, Yi Wang, Weiqi Sheng, Xinxiang Li, Aiping Zhou, Zhen Zhang, Guichao Li, Sanjun Cai, Ruihua Xu, Jin Li, Suzhan Zhang

Pages: 423-425 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer working group

Pages: 84-98 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer working group

Pages: 99-116 HTML

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer working group

Pages: 117-134 HTML

NHCPRC Guidelines

National Health Commission guidelines for diagnosis and treatment of colorectal cancer in China (2025 edition, English version)

Department of Medical Administration, National Health Commission of the People’s Republic of China; Chinese Medical Association Oncology Branch

Pages: 949-961 HTML

National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version)

National Health Commission of the People’s Republic of China; Society of Oncology, Chinese Medical Association

Pages: 197-232 HTML